Morgan Stanley Reports On Psychedelics: A Potential Long-Term Investment Portfolio For An Emerging Market

Counterpoint Global is Morgan Stanley’s (NYSE: MS) Investment Management division in charge of understanding new or “disruptive” market opportunities that hold “the potential to trigger far-reaching consequences” and therefore constitute a likely sound, long-term investment, and this report focuses on psychedelics for medical purposes.  

As first shared by Psychedelic Alpha, the document provides a concise but solid overview of what psychedelics are and what is their action mechanism, their research history and which compounds are currently under advanced clinical trials. 

The report further explains the team’s account of why psychedelics are disruptive, what unmet medical needs …

Full story available on Benzinga.com

Morgan Stanley Reports On Psychedelics: A Potential Long-Term Investment Portfolio For An Emerging Market on Benzinga